ID   OLR1_HUMAN              Reviewed;         273 AA.
AC   P78380; A8K7V9; B4DI48; G3V1I4; Q2PP00; Q7Z484;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   03-AUG-2022, entry version 198.
DE   RecName: Full=Oxidized low-density lipoprotein receptor 1;
DE            Short=Ox-LDL receptor 1;
DE   AltName: Full=C-type lectin domain family 8 member A;
DE   AltName: Full=Lectin-like oxidized LDL receptor 1;
DE            Short=LOX-1;
DE            Short=Lectin-like oxLDL receptor 1;
DE            Short=hLOX-1;
DE   AltName: Full=Lectin-type oxidized LDL receptor 1;
DE   Contains:
DE     RecName: Full=Oxidized low-density lipoprotein receptor 1, soluble form;
GN   Name=OLR1; Synonyms=CLEC8A, LOX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=9052782; DOI=10.1038/386073a0;
RA   Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y.,
RA   Tanaka T., Miwa S., Katsura Y., Kita T., Masaki T.;
RT   "An endothelial receptor for oxidized low-density lipoprotein.";
RL   Nature 386:73-77(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9763655; DOI=10.1159/000015059;
RA   Li X., Bouzyk M.M., Wang X.;
RT   "Assignment of the human oxidized low-density lipoprotein receptor gene
RT   (OLR1) to chromosome 12p13.1-->p12.3, and identification of a polymorphic
RT   CA-repeat marker in the OLR1 gene.";
RL   Cytogenet. Cell Genet. 82:34-36(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DOMAIN, DISULFIDE BONDS,
RP   GLYCOSYLATION, AND MUTAGENESIS OF CYS-144; CYS-155; CYS-172; ASN-183;
RP   209-ARG-ASN-210; HIS-226; ARG-229; ARG-231; 235-SER-GLN-236; SER-240;
RP   CYS-243; CYS-256; CYS-264 AND 267-LYS--GLN-273.
RX   PubMed=11256994; DOI=10.1242/jcs.114.7.1273;
RA   Shi X., Niimi S., Ohtani T., Machida S.;
RT   "Characterization of residues and sequences of the carbohydrate recognition
RT   domain required for cell surface localization and ligand binding of human
RT   lectin-like oxidized LDL receptor.";
RL   J. Cell Sci. 114:1273-1282(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=9828121; DOI=10.1006/geno.1998.5561;
RA   Yamanaka S., Zhang X.-Y., Miura K., Kim S., Iwao H.;
RT   "The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a
RT   novel member of the natural killer gene complex with a unique expression
RT   profile.";
RL   Genomics 54:191-199(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN MYOCARDIAL
RP   INFARCTION, AND VARIANT ASN-167.
RX   PubMed=12646194; DOI=10.1016/s0006-291x(03)00326-7;
RA   Tatsuguchi M., Furutani M., Hinagata J., Tanaka T., Furutani Y.,
RA   Imamura S., Kawana M., Masaki T., Kasanuki H., Sawamura T., Matsuoka R.;
RT   "Oxidized LDL receptor gene (OLR1) is associated with the risk of
RT   myocardial infarction.";
RL   Biochem. Biophys. Res. Commun. 303:247-250(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Millar D.S.;
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ASN-167.
RC   TISSUE=Corpus callosum, and Synovial cell;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION.
RX   PubMed=11821063; DOI=10.1016/s0014-5793(01)03297-5;
RA   Hayashida K., Kume N., Minami M., Kita T.;
RT   "Lectin-like oxidized LDL receptor-1 (LOX-1) supports adhesion of
RT   mononuclear leukocytes and a monocyte-like cell line THP-1 cells under
RT   static and flow conditions.";
RL   FEBS Lett. 511:133-138(2002).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12354387; DOI=10.1016/s1074-7613(02)00388-6;
RA   Delneste Y., Magistrelli G., Gauchat J.-F., Haeuw J.-P., Aubry J.-F.,
RA   Nakamura K., Kawakami-Honda N., Goetsch L., Sawamura T., Bonnefoy J.-Y.,
RA   Jeannin P.;
RT   "Involvement of LOX-1 in dendritic cell-mediated antigen cross-
RT   presentation.";
RL   Immunity 17:353-362(2002).
RN   [15]
RP   INVOLVEMENT IN ALZHEIMER DISEASE.
RX   PubMed=12384789; DOI=10.1007/s00439-002-0802-7;
RA   Luedecking-Zimmer E., DeKosky S.T., Chen Q., Barmada M.M., Kamboh M.I.;
RT   "Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for
RT   Alzheimer's disease on chromosome 12.";
RL   Hum. Genet. 111:443-451(2002).
RN   [16]
RP   INDUCTION.
RX   PubMed=12878212; DOI=10.1016/s0006-291x(03)01295-6;
RA   Hu B., Li D., Sawamura T., Mehta J.L.;
RT   "Oxidized LDL through LOX-1 modulates LDL-receptor expression in human
RT   coronary artery endothelial cells.";
RL   Biochem. Biophys. Res. Commun. 307:1008-1012(2003).
RN   [17]
RP   INVOLVEMENT IN MYOCARDIAL INFARCTION.
RX   PubMed=12810610; DOI=10.1161/01.cir.0000074207.85796.36;
RA   Chen Q., Reis S.E., Kammerer C., Craig W.Y., LaPierre S.E., Zimmer E.L.,
RA   McNamara D.M., Pauly D.F., Sharaf B., Holubkov R., Bairey Merz C.N.,
RA   Sopko G., Bontempo F., Kamboh M.I.;
RT   "Genetic variation in lectin-like oxidized low-density lipoprotein receptor
RT   1 (LOX1) gene and the risk of coronary artery disease.";
RL   Circulation 107:3146-3151(2003).
RN   [18]
RP   INVOLVEMENT IN ALZHEIMER DISEASE.
RX   PubMed=12807963; DOI=10.1136/jmg.40.6.424;
RA   Lambert J.-C., Luedecking-Zimmer E., Merrot S., Hayes A., Thaker U.,
RA   Desai P., Houzet A., Hermant X., Cottel D., Pritchard A., Iwatsubo T.,
RA   Pasquier F., Frigard B., Conneally P.M., Chartier-Harlin M.-C.,
RA   DeKosky S.T., Lendon C., Mann D., Kamboh M.I., Amouyel P.;
RT   "Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1)
RT   gene with Alzheimer's disease.";
RL   J. Med. Genet. 40:424-430(2003).
RN   [19]
RP   HOMODIMERIZATION, INTERCHAIN DISULFIDE BOND, AND MUTAGENESIS OF CYS-140.
RX   PubMed=15000751; DOI=10.1089/104454904322759920;
RA   Xie Q., Matsunaga S., Niimi S., Ogawa S., Tokuyasu K., Sakakibara Y.,
RA   Machida S.;
RT   "Human lectin-like oxidized low-density lipoprotein receptor-1 functions as
RT   a dimer in living cells.";
RL   DNA Cell Biol. 23:111-117(2004).
RN   [20]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE.
RX   PubMed=15060104; DOI=10.1136/jmg.2003.016980;
RA   Bertram L., Parkinson M., Mullin K., Menon R., Blacker D., Tanzi R.E.;
RT   "No association between a previously reported OLR1 3' UTR polymorphism and
RT   Alzheimer's disease in a large family sample.";
RL   J. Med. Genet. 41:286-288(2004).
RN   [21]
RP   LACK OF INVOLVEMENT IN ALZHEIMER DISEASE.
RX   PubMed=15276231; DOI=10.1016/j.neulet.2004.05.023;
RA   Pritchard A., St Clair D., Lemmon H., Mann D.M.A., Lendon C.;
RT   "No association between polymorphisms in the lectin-like oxidised low
RT   density lipoprotein receptor (ORL1) gene on chromosome 12 and Alzheimer's
RT   disease in a UK cohort.";
RL   Neurosci. Lett. 366:126-129(2004).
RN   [22]
RP   INVOLVEMENT IN MYOCARDIAL INFARCTION.
RX   PubMed=15976314; DOI=10.1161/01.res.0000174563.62625.8e;
RA   Mango R., Biocca S., del Vecchio F., Clementi F., Sangiuolo F., Amati F.,
RA   Filareto A., Grelli S., Spitalieri P., Filesi I., Favalli C., Lauro R.,
RA   Mehta J.L., Romeo F., Novelli G.;
RT   "In vivo and in vitro studies support that a new splicing isoform of OLR1
RT   gene is protective against acute myocardial infarction.";
RL   Circ. Res. 97:152-158(2005).
RN   [23]
RP   INVOLVEMENT IN ALZHEIMER DISEASE.
RX   PubMed=15860461; DOI=10.1093/gerona/60.3.280;
RA   D'Introno A., Solfrizzi V., Colacicco A.M., Capurso C., Torres F.,
RA   Capurso S.A., Capurso A., Panza F.;
RT   "Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and
RT   risk of Alzheimer's disease.";
RL   J. Gerontol. 60:280-284(2005).
RN   [24]
RP   DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 22-LYS--LYS-25 AND GLU-70.
RX   PubMed=15935375; DOI=10.1016/j.yjmcc.2005.05.001;
RA   Chen M., Sawamura T.;
RT   "Essential role of cytoplasmic sequences for cell-surface sorting of the
RT   lectin-like oxidized LDL receptor-1 (LOX-1).";
RL   J. Mol. Cell. Cardiol. 39:553-561(2005).
RN   [25]
RP   GLYCOSYLATION AT ASN-139.
RX   PubMed=22688517; DOI=10.1007/s10719-012-9408-z;
RA   Qian Y., Zhang X., Zhou L., Yun X., Xie J., Xu J., Ruan Y., Ren S.;
RT   "Site-specific N-glycosylation identification of recombinant human lectin-
RT   like oxidized low density lipoprotein receptor-1 (LOX-1).";
RL   Glycoconj. J. 29:399-409(2012).
RN   [26]
RP   PALMITOYLATION AT CYS-36 AND CYS-46, AND SUBCELLULAR LOCATION.
RX   PubMed=23583401; DOI=10.1016/j.bbrc.2013.03.120;
RA   Kumano-Kuramochi M., Xie Q., Kajiwara S., Komba S., Minowa T., Machida S.;
RT   "Lectin-like oxidized LDL receptor-1 is palmitoylated and internalizes
RT   ligands via caveolae/raft-dependent endocytosis.";
RL   Biochem. Biophys. Res. Commun. 434:594-599(2013).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH N.MENINGITIDIS ADHESIN
RP   A (MICROBIAL INFECTION).
RX   PubMed=27302108; DOI=10.1038/srep27996;
RA   Scietti L., Sampieri K., Pinzuti I., Bartolini E., Benucci B., Liguori A.,
RA   Haag A.F., Lo Surdo P., Pansegrau W., Nardi-Dei V., Santini L., Arora S.,
RA   Leber X., Rindi S., Savino S., Costantino P., Maione D., Merola M.,
RA   Speziale P., Bottomley M.J., Bagnoli F., Masignani V., Pizza M.,
RA   Scharenberg M., Schlaeppi J.M., Nissum M., Liberatori S.;
RT   "Exploring host-pathogen interactions through genome wide protein
RT   microarray analysis.";
RL   Sci. Rep. 6:27996-27996(2016).
RN   [28]
RP   INTERACTION WITH N.MENINGITIDIS ADHESIN A (MICROBIAL INFECTION).
RX   PubMed=30327444; DOI=10.1128/mbio.01914-18;
RA   Liguori A., Dello Iacono L., Maruggi G., Benucci B., Merola M.,
RA   Lo Surdo P., Lopez-Sagaseta J., Pizza M., Malito E., Bottomley M.J.;
RT   "NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions
RT   Competed by Meningococcus B Vaccine-Elicited Human Antibodies.";
RL   MBio 9:0-0(2018).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 136-270, SUBUNIT, AND DISULFIDE
RP   BONDS.
RX   PubMed=15695803; DOI=10.1074/jbc.m500768200;
RA   Park H., Adsit F.G., Boyington J.C.;
RT   "The 1.4 angstrom crystal structure of the human oxidized low density
RT   lipoprotein receptor lox-1.";
RL   J. Biol. Chem. 280:13593-13599(2005).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 143-271, SUBUNIT, DISULFIDE BONDS,
RP   AND MUTAGENESIS OF TRP-150; ARG-208; ARG-209; HIS-226; ARG-229; ARG-231 AND
RP   ARG-248.
RX   PubMed=15939022; DOI=10.1016/j.str.2005.03.016;
RA   Ohki I., Ishigaki T., Oyama T., Matsunaga S., Xie Q., Ohnishi-Kameyama M.,
RA   Murata T., Tsuchiya D., Machida S., Morikawa K., Tate S.;
RT   "Crystal structure of human lectin-like, oxidized low-density lipoprotein
RT   receptor 1 ligand binding domain and its ligand recognition mode to
RT   oxLDL.";
RL   Structure 13:905-917(2005).
CC   -!- FUNCTION: Receptor that mediates the recognition, internalization and
CC       degradation of oxidatively modified low density lipoprotein (oxLDL) by
CC       vascular endothelial cells. OxLDL is a marker of atherosclerosis that
CC       induces vascular endothelial cell activation and dysfunction, resulting
CC       in pro-inflammatory responses, pro-oxidative conditions and apoptosis.
CC       Its association with oxLDL induces the activation of NF-kappa-B through
CC       an increased production of intracellular reactive oxygen and a variety
CC       of pro-atherogenic cellular responses including a reduction of nitric
CC       oxide (NO) release, monocyte adhesion and apoptosis. In addition to
CC       binding oxLDL, it acts as a receptor for the HSP70 protein involved in
CC       antigen cross-presentation to naive T-cells in dendritic cells, thereby
CC       participating in cell-mediated antigen cross-presentation. Also
CC       involved in inflammatory process, by acting as a leukocyte-adhesion
CC       molecule at the vascular interface in endotoxin-induced inflammation.
CC       Also acts as a receptor for advanced glycation end (AGE) products,
CC       activated platelets, monocytes, apoptotic cells and both Gram-negative
CC       and Gram-positive bacteria. {ECO:0000269|PubMed:11821063,
CC       ECO:0000269|PubMed:12354387, ECO:0000269|PubMed:9052782}.
CC   -!- FUNCTION: (Microbial infection) May serve as a receptor for adhesin A
CC       variant 3 (nadA) of N.meningitidis. {ECO:0000305|PubMed:27302108}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. May form a hexamer composed of 3
CC       homodimers. Interacts with HSP70. {ECO:0000269|PubMed:11256994,
CC       ECO:0000269|PubMed:15695803, ECO:0000269|PubMed:15939022}.
CC   -!- SUBUNIT: (Microbial infection) Binds to the head and beginning of the
CC       coiled stalk of N.meningitidis adhesin A (nadA) variant 3; binding can
CC       be abrogated by monoclonal antibodies against the specific regions of
CC       NadA. Binding occurs in protein microarrays, in solution and when LOX-1
CC       is expressed on the cell surface. {ECO:0000269|PubMed:27302108,
CC       ECO:0000269|PubMed:30327444}.
CC   -!- INTERACTION:
CC       P78380; P50991: CCT4; NbExp=3; IntAct=EBI-7151999, EBI-356876;
CC       P78380; P78380: OLR1; NbExp=4; IntAct=EBI-7151999, EBI-7151999;
CC       P78380; P17987: TCP1; NbExp=5; IntAct=EBI-7151999, EBI-356553;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor. Cell membrane;
CC       Single-pass type II membrane protein. Membrane raft. Secreted. Note=A
CC       secreted form also exists. Localization to membrane rafts requires
CC       palmitoylation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P78380-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78380-2; Sequence=VSP_042555;
CC       Name=3;
CC         IsoId=P78380-3; Sequence=VSP_045277;
CC   -!- TISSUE SPECIFICITY: Expressed at high level in endothelial cells and
CC       vascular-rich organs such as placenta, lung, liver and brain, aortic
CC       intima, bone marrow, spinal cord and substantia nigra. Also expressed
CC       at the surface of dendritic cells. Widely expressed at intermediate and
CC       low level. {ECO:0000269|PubMed:12354387, ECO:0000269|PubMed:9052782,
CC       ECO:0000269|PubMed:9828121}.
CC   -!- INDUCTION: By inflammatory cytokines such as TNF, IFNG/IFN-gamma,
CC       IL6/interleukin-6 and by pathological conditions such as
CC       hyperlipidemia, hypertension and diabetes mellitus. Up-regulated in
CC       atherosclerotic lesions, by oxLDL, reactive oxygen species and fluid
CC       shear stress, suggesting that it may participate in amplification of
CC       oxLDL-induced vascular dysfunction. {ECO:0000269|PubMed:12878212,
CC       ECO:0000269|PubMed:9828121}.
CC   -!- DOMAIN: The cytoplasmic region is required for subcellular sorting on
CC       the cell surface.
CC   -!- DOMAIN: The C-type lectin domain mediates the recognition and binding
CC       of oxLDL.
CC   -!- PTM: The intrachain disulfide-bonds prevent N-glycosylation at some
CC       sites.
CC   -!- PTM: N-glycosylated.
CC   -!- DISEASE: Note=Independent association genetic studies have implicated
CC       OLR1 gene variants in myocardial infarction susceptibility.
CC   -!- DISEASE: Note=OLR1 may be involved in Alzheimer disease (AD).
CC       Involvement in AD is however unclear: according to some authors
CC       (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in
CC       OLR1 modify the risk of AD, while according to others (PubMed:15000751
CC       and PubMed:15060104) they do not. {ECO:0000269|PubMed:12384789,
CC       ECO:0000269|PubMed:12807963, ECO:0000269|PubMed:15860461}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Oxidized LDL receptor;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_249";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB010710; BAA24580.1; -; mRNA.
DR   EMBL; AF035776; AAC82329.1; -; mRNA.
DR   EMBL; AF079167; AAC97927.1; -; Genomic_DNA.
DR   EMBL; AF079166; AAC97927.1; JOINED; Genomic_DNA.
DR   EMBL; AF079164; AAC97927.1; JOINED; Genomic_DNA.
DR   EMBL; AF079165; AAC97927.1; JOINED; Genomic_DNA.
DR   EMBL; AB102861; BAC81565.1; -; mRNA.
DR   EMBL; AJ131757; CAB38175.1; -; Genomic_DNA.
DR   EMBL; BX344276; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK292124; BAF84813.1; -; mRNA.
DR   EMBL; AK295409; BAG58360.1; -; mRNA.
DR   EMBL; DQ314885; ABC40744.1; -; Genomic_DNA.
DR   EMBL; AC024224; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471094; EAW96157.1; -; Genomic_DNA.
DR   EMBL; CH471094; EAW96158.1; -; Genomic_DNA.
DR   EMBL; BC022295; AAH22295.1; -; mRNA.
DR   CCDS; CCDS53745.1; -. [P78380-2]
DR   CCDS; CCDS53746.1; -. [P78380-3]
DR   CCDS; CCDS8618.1; -. [P78380-1]
DR   RefSeq; NP_001166103.1; NM_001172632.1. [P78380-2]
DR   RefSeq; NP_001166104.1; NM_001172633.1. [P78380-3]
DR   RefSeq; NP_002534.1; NM_002543.3. [P78380-1]
DR   PDB; 1YPO; X-ray; 3.00 A; A/B/C/D/E/F/G/H=142-272.
DR   PDB; 1YPQ; X-ray; 1.40 A; A/B=136-270.
DR   PDB; 1YPU; X-ray; 2.05 A; A/B=136-270.
DR   PDB; 1YXJ; X-ray; 1.78 A; A/B=143-271.
DR   PDB; 1YXK; X-ray; 2.40 A; A/B=136-270.
DR   PDB; 3VLG; X-ray; 2.30 A; A=133-273.
DR   PDB; 6TL7; X-ray; 1.11 A; A/B=143-273.
DR   PDB; 6TL9; X-ray; 2.73 A; A/B/C/D/E/F/G/H=143-273.
DR   PDB; 6TLA; X-ray; 2.16 A; A/B/C=129-273.
DR   PDBsum; 1YPO; -.
DR   PDBsum; 1YPQ; -.
DR   PDBsum; 1YPU; -.
DR   PDBsum; 1YXJ; -.
DR   PDBsum; 1YXK; -.
DR   PDBsum; 3VLG; -.
DR   PDBsum; 6TL7; -.
DR   PDBsum; 6TL9; -.
DR   PDBsum; 6TLA; -.
DR   AlphaFoldDB; P78380; -.
DR   SMR; P78380; -.
DR   BioGRID; 111021; 23.
DR   DIP; DIP-42040N; -.
DR   IntAct; P78380; 9.
DR   MINT; P78380; -.
DR   STRING; 9606.ENSP00000309124; -.
DR   ChEMBL; CHEMBL3421522; -.
DR   GlyGen; P78380; 2 sites.
DR   iPTMnet; P78380; -.
DR   PhosphoSitePlus; P78380; -.
DR   SwissPalm; P78380; -.
DR   BioMuta; OLR1; -.
DR   DMDM; 73621335; -.
DR   jPOST; P78380; -.
DR   MassIVE; P78380; -.
DR   MaxQB; P78380; -.
DR   PaxDb; P78380; -.
DR   PeptideAtlas; P78380; -.
DR   PRIDE; P78380; -.
DR   ProteomicsDB; 32344; -.
DR   ProteomicsDB; 57601; -. [P78380-1]
DR   ProteomicsDB; 57602; -. [P78380-2]
DR   ABCD; P78380; 33 sequenced antibodies.
DR   Antibodypedia; 11685; 672 antibodies from 41 providers.
DR   DNASU; 4973; -.
DR   Ensembl; ENST00000309539.8; ENSP00000309124.3; ENSG00000173391.9. [P78380-1]
DR   Ensembl; ENST00000432556.6; ENSP00000405116.2; ENSG00000173391.9. [P78380-2]
DR   Ensembl; ENST00000545927.5; ENSP00000439251.1; ENSG00000173391.9. [P78380-3]
DR   GeneID; 4973; -.
DR   KEGG; hsa:4973; -.
DR   MANE-Select; ENST00000309539.8; ENSP00000309124.3; NM_002543.4; NP_002534.1.
DR   UCSC; uc001qxo.2; human. [P78380-1]
DR   CTD; 4973; -.
DR   DisGeNET; 4973; -.
DR   GeneCards; OLR1; -.
DR   HGNC; HGNC:8133; OLR1.
DR   HPA; ENSG00000173391; Tissue enhanced (lung, placenta).
DR   MalaCards; OLR1; -.
DR   MIM; 602601; gene+phenotype.
DR   neXtProt; NX_P78380; -.
DR   NIAGADS; ENSG00000173391; -.
DR   OpenTargets; ENSG00000173391; -.
DR   PharmGKB; PA31920; -.
DR   VEuPathDB; HostDB:ENSG00000173391; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   GeneTree; ENSGT00940000161941; -.
DR   InParanoid; P78380; -.
DR   OMA; HSSFPFW; -.
DR   PhylomeDB; P78380; -.
DR   TreeFam; TF336674; -.
DR   PathwayCommons; P78380; -.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; P78380; -.
DR   BioGRID-ORCS; 4973; 13 hits in 1069 CRISPR screens.
DR   ChiTaRS; OLR1; human.
DR   EvolutionaryTrace; P78380; -.
DR   GeneWiki; OLR1; -.
DR   GenomeRNAi; 4973; -.
DR   Pharos; P78380; Tbio.
DR   PRO; PR:P78380; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P78380; protein.
DR   Bgee; ENSG00000173391; Expressed in right lung and 128 other tissues.
DR   ExpressionAtlas; P78380; baseline and differential.
DR   Genevisible; P78380; HS.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005041; F:low-density lipoprotein particle receptor activity; IBA:GO_Central.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0008219; P:cell death; IBA:GO_Central.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IBA:GO_Central.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; TAS:ProtInc.
DR   CDD; cd03593; CLECT_NK_receptors_like; 1.
DR   Gene3D; 3.10.100.10; -; 1.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR013600; Ly49_N.
DR   InterPro; IPR033992; NKR-like_CTLD.
DR   Pfam; PF00059; Lectin_C; 1.
DR   Pfam; PF08391; Ly49; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
KW   Coiled coil; Disulfide bond; Glycoprotein; Immunity; Inflammatory response;
KW   Lectin; Lipoprotein; Membrane; Palmitate; Receptor; Reference proteome;
KW   Secreted; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..273
FT                   /note="Oxidized low-density lipoprotein receptor 1"
FT                   /id="PRO_0000017443"
FT   CHAIN           ?..273
FT                   /note="Oxidized low-density lipoprotein receptor 1, soluble
FT                   form"
FT                   /id="PRO_0000017444"
FT   TOPO_DOM        1..36
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        37..57
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        58..273
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          151..265
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          58..150
FT                   /note="Neck"
FT   COILED          64..123
FT                   /evidence="ECO:0000255"
FT   SITE            183
FT                   /note="Not glycosylated"
FT                   /evidence="ECO:0000305"
FT   LIPID           36
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:23583401"
FT   LIPID           46
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:23583401"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        139
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22688517"
FT   DISULFID        140
FT                   /note="Interchain"
FT   DISULFID        144..155
FT   DISULFID        172..264
FT   DISULFID        243..256
FT   VAR_SEQ         142..273
FT                   /note="APCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQ
FT                   AISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVY
FT                   AENCILAAFSICQKKANLRAQ -> GLHPASNFLFQFSILDGAVSEEPQLPMALGGRFS
FT                   FDAPLI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042555"
FT   VAR_SEQ         189..273
FT                   /note="DFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPS
FT                   GTCAYIQRGAVYAENCILAAFSICQKKANLRAQ -> I (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_045277"
FT   VARIANT         167
FT                   /note="K -> N (myocardial infarction susceptibility;
FT                   dbSNP:rs11053646)"
FT                   /evidence="ECO:0000269|PubMed:12646194,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_023200"
FT   MUTAGEN         22..25
FT                   /note="KKAK->EEAE: Impairs sorting into the cell surface
FT                   but retains ability to bind oxLDL. Abolishes sorting into
FT                   the cell surface; when associated with K-69."
FT                   /evidence="ECO:0000269|PubMed:15935375"
FT   MUTAGEN         70
FT                   /note="E->K: Abolishes sorting into the cell surface; when
FT                   associated with 22-E--E-25."
FT                   /evidence="ECO:0000269|PubMed:15935375"
FT   MUTAGEN         140
FT                   /note="C->S: Abolishes homodimerization."
FT                   /evidence="ECO:0000269|PubMed:15000751"
FT   MUTAGEN         144
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-155; S-172; S-243;
FT                   S-256 and S-264."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         150
FT                   /note="W->A: Abolishes binding to acetylated LDL (AcLDL),
FT                   probably due to inappropriate homodimerization."
FT                   /evidence="ECO:0000269|PubMed:15939022"
FT   MUTAGEN         155
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-144; S-172; S-243;
FT                   S-256 and S-264."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         172
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-144; S-155; S-243;
FT                   S-256 and S-264."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         183
FT                   /note="N->Q: Does not affect glycosylation state."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         193
FT                   /note="Q->L: Impairs binding to acetylated LDL (AcLDL);
FT                   when associated with 198-AA-199."
FT   MUTAGEN         198..199
FT                   /note="SS->AA: Impairs binding to acetylated LDL (AcLDL);
FT                   when associated with L-193."
FT   MUTAGEN         208
FT                   /note="R->N: Does not affect subcellular location but
FT                   displays a strongly reduced affinity for acetylated LDL
FT                   (AcLDL)."
FT                   /evidence="ECO:0000269|PubMed:15939022"
FT   MUTAGEN         209..210
FT                   /note="RN->LL: Abolishes binding to acetylated LDL
FT                   (AcLDL)."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         209
FT                   /note="R->N: Does not affect binding to acetylated LDL
FT                   (AcLDL)."
FT                   /evidence="ECO:0000269|PubMed:15939022"
FT   MUTAGEN         226
FT                   /note="H->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:11256994,
FT                   ECO:0000269|PubMed:15939022"
FT   MUTAGEN         226
FT                   /note="H->Q: Abolishes binding to acetylated LDL (AcLDL);
FT                   when associated with N-229 and N-231."
FT                   /evidence="ECO:0000269|PubMed:11256994,
FT                   ECO:0000269|PubMed:15939022"
FT   MUTAGEN         229
FT                   /note="R->N: Does not affect subcellular location but
FT                   displays a reduced affinity for acetylated LDL (AcLDL).
FT                   Abolishes binding to acetylated LDL (AcLDL); when
FT                   associated with Q-226 and N-231."
FT                   /evidence="ECO:0000269|PubMed:11256994,
FT                   ECO:0000269|PubMed:15939022"
FT   MUTAGEN         231
FT                   /note="R->N: Abolishes binding to acetylated LDL (AcLDL).
FT                   Abolishes binding to AcLDL; when associated with Q-226 and
FT                   N-229."
FT                   /evidence="ECO:0000269|PubMed:11256994,
FT                   ECO:0000269|PubMed:15939022"
FT   MUTAGEN         235..236
FT                   /note="SQ->AL: Impairs binding to acetylated LDL (AcLDL);
FT                   when associated with A-240."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         240
FT                   /note="S->A: Impairs binding to acetylated LDL (AcLDL);
FT                   when associated with 235-AL-236."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         243
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-144; S-155; S-172;
FT                   S-256 and S-264."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         248
FT                   /note="R->N: Does not affect subcellular location but
FT                   displays a reduced affinity for acetylated LDL (AcLDL)."
FT                   /evidence="ECO:0000269|PubMed:15939022"
FT   MUTAGEN         256
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-144; S-155; S-172;
FT                   S-243 and S-264."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         264
FT                   /note="C->S: Abolishes sorting into the cell surface and
FT                   binding to acetylated LDL (AcLDL) while increasing
FT                   N-glycosylation; when associated with S-144; S-155; S-172;
FT                   S-243 and S-256."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   MUTAGEN         267..273
FT                   /note="Missing: Impairs protein folding and transport."
FT                   /evidence="ECO:0000269|PubMed:11256994"
FT   STRAND          148..151
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          154..158
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   HELIX           165..174
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   HELIX           185..194
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   TURN            195..197
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          202..210
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          225..227
FT                   /evidence="ECO:0007829|PDB:1YPO"
FT   STRAND          230..233
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          242..247
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          250..255
FT                   /evidence="ECO:0007829|PDB:6TL7"
FT   STRAND          260..267
FT                   /evidence="ECO:0007829|PDB:6TL7"
SQ   SEQUENCE   273 AA;  30959 MW;  852DE6595DC3D361 CRC64;
     MTFDDLKIQT VKDQPDEKSN GKKAKGLQFL YSPWWCLAAA TLGVLCLGLV VTIMVLGMQL
     SQVSDLLTQE QANLTHQKKK LEGQISARQQ AEEASQESEN ELKEMIETLA RKLNEKSKEQ
     MELHHQNLNL QETLKRVANC SAPCPQDWIW HGENCYLFSS GSFNWEKSQE KCLSLDAKLL
     KINSTADLDF IQQAISYSSF PFWMGLSRRN PSYPWLWEDG SPLMPHLFRV RGAVSQTYPS
     GTCAYIQRGA VYAENCILAA FSICQKKANL RAQ
//
